Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Take part in the 4th edition of the Transatlantic Exchanges dedicated to radioligand therapies
Gustave Roussy and the Dana-Farber Cancer Institute (Boston, United States) are organising the fourth edition of the Transatlantic Exchange oncology conference on 19 March 2025 at the Hyatt Regency Paris Étoile hotel. The theme will be “Radiopharmaceutical Therapy Meets Oncology.”
Published on
Gustave Roussy and the Dana-Farber Cancer Institute (Boston, United States) are organising the fourth edition of the Transatlantic Exchange oncology conference on 19 March 2025 at the Hyatt Regency Paris Étoile hotel. The theme will be “Radiopharmaceutical Therapy Meets Oncology.”
Free registration (in-person or virtual): https://events.medscapelive.org/website/82041/.
After the 2024 edition dedicated to liquid biopsy, organised in Boston, the Franco-American oncology conference Transatlantic Exchange returns this year to Paris to discuss the latest advances related to radioligand therapies.
Physician-researchers will share their expertise on theranostics for early cancer detection and characterisation, the latest clinical advances concerning innovative radiopharmaceuticals, and the prospects for the development of radioligand treatments.
A radioligand treatment, or radionuclide therapy, is an innovative approach in oncology that combines a drug specifically targeting tumour cells with a radioactive isotope. This therapy delivers a radiation dose directly to cancer cells while sparing healthy tissues, offering increased precision and new perspectives for treating numerous cancers.
This edition of the Transatlantic Exchange will be chaired by Professor Toni Choueiri, Medical Director of International Strategic Initiatives and Director of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute and Harvard Medical School, as well as by Professor Karim Fizazi, Head of the International Academic Network at Gustave Roussy and Head of the Genitourinary Cancer Committee at the Institute.
Registrations open
The conference, organised with the support of the Institut Servier and Medscape Medical Affairs, is free and open to healthcare professionals interested in oncology.
Registration on the website: https://events.medscapelive.org/website/82041/.
Last news
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
-
Newsweek Ranking: Gustave Roussy Named Europe’s Leading Cancer Centre and Third Best Worldwide
The 2027 edition of Newsweek’s World's Best Specialized Hospitals ranking once again recognises Gustave Roussy as the leading cancer centre in France and Europe, and the third best worldwide. This distinction highlights the excellence of the Institute’s care and research, as well as the daily commitment of all its professionals.
-
Living with and beyond cancer: the promises and challenges of digital health
In a Viewpoint article published in The Lancet Digital Health, Drs Ines Vaz-Luis and Maria Alice Franzoi, together with Emmanuel Mussault, a patient partner at the PRISM University Hospital Institute, examine the role that digital tools can play in supporting people living with and beyond cancer. Their central message is that these technologies can support more personalised and accessible care, but their value depends primarily on how they are integrated into care pathways, the human support provided, their ability to address individual needs and their evaluation in real-world settings.
-
Gustave Roussy and The Lancet launch an international lecture series on innovations transforming cancer care
The inaugural lecture in the “Lecture Series on Cancer Breakthroughs” will take place on Friday 18 September at 5:00 pm. It will be delivered by Professor Timothy R. Rebbeck, a leading cancer prevention specialist at Harvard University and the Dana-Farber Cancer Institute.
